-
StreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus'
Thursday, June 9, 2016 - 10:49am | 389Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were volatile Thursday morning. The company is the central focus of The Street Sweeper's latest short thesis. The Street Sweeper's Sony Colberg offered eight reasons why investors should consider running away from the stock and not "join this...
-
Relypsa Surges 30% Following Setback From Rival AstraZeneca
Friday, May 27, 2016 - 8:09am | 217Read More...Shares of Relypsa Inc (NASDAQ: RLYP) surged higher by more than 30 percent early Friday morning on no corporate news or rumors. According to the TheStreet'sAdam Feuerstein, Relypisa scored a "big win" on Friday after its chief rival AstraZeneca plc (ADR) (NYSE: AZN) confirmed the...
-
Relypsa Up 10% Following Encouraging Phase 1 Study Results
Tuesday, January 26, 2016 - 9:30am | 262Read More...Shares of Relypsa Inc (NASDAQ: RLYP), a biopharmaceutical company that focuses on non-absorbed polymeric drugs to tread disorders in the areas of renal, cardiovascular and metabolic diseases, were trading higher by more than 10 percent early Tuesday morning. Relypsa announced after Monday's close...
-
Relypsa Lost Major Ground; Feuerstein Tweets Favus Report Said 'Nothing New'
Friday, January 8, 2016 - 9:17am | 331Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 8 percent early Friday morning. The stock plunged more than 13 percent on Thursday following a bear research report by Elliot Favus of Favus Institutional Research. Adam Feuerstein, a senior columnist with The Street and known...
-
Shares Of Relypsa Hit Hard Following New Employment Inducement Grants, Confidential Treatment Order
Wednesday, January 6, 2016 - 12:24pm | 122Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading lower by nearly 4 percent at $25.78 late Wednesday morning. Relypsa announced on Tuesday its compensation committee granted 10 new employees the option to purchase an aggregate of 34,600 shares of the company's stock at a purchase price of $...
-
Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share
Thursday, December 24, 2015 - 8:53am | 122Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target. The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (...
-
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'
Friday, December 4, 2015 - 2:14pm | 432Read More...Relypsa Inc (NASDAQ: RLYP) shares are up more than 16 percent on Friday afternoon after unconfirmed reports that Merck & Co., Inc. (NYSE: MRK) could make a bid for the $1.07 billion bio therapeutic company. A source familiar with the matter told Benzinga Merck is not involved with a bid, but...
-
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Thursday, July 3, 2014 - 10:36am | 873Read More...Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...
-
Market Wrap For December 10: Fed Meeting One Week Away
Tuesday, December 10, 2013 - 5:41pm | 1996Read More...After starting the week hitting record closes yesterday, major indices slipped in today's trading session. Investors are anxiously awaiting next week's Federal Reserve meeting which it is becoming more and more apparent that tapering is set to begin sooner, rather than later. The meetings will...
